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Abstract
Background: Acute myeloid leukemia (AML) is a heterogeneous disease with an overall poor prognosis. Gene expression
profiling studies of patients with AML has provided key insights into disease pathogenesis while exposing potential
diagnostic and prognostic markers and therapeutic targets. A systematic comparison of the large body of gene expression
profiling studies in AML has the potential to test the extensibility of conclusions based on single studies and provide further
insights into AML.
Methodology/Principal Findings: In this study, we systematically compared 25 published reports of gene expression
profiling in AML. There were a total of 4,918 reported genes of which one third were reported in more than one study. We
found that only a minority of reported prognostically-associated genes (9.6%) were replicated in at least one other study. In
a combined analysis, we comprehensively identified both gene sets and functional gene categories and pathways that
exhibited significant differential regulation in distinct prognostic categories, including many previously unreported
associations.
Conclusions/Significance: We developed a novel approach for granular, cross-study analysis of gene-by-gene data and
their relationships with established prognostic features and patient outcome. We identified many robust novel prognostic
molecular features in AML that were undetected in prior studies, and which provide insights into AML pathogenesis with
potential diagnostic, prognostic, and therapeutic implications. Our database and integrative analysis are available online
(http://gat.stamlab.org).
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease
with overall poor survival. The prognosis of AML is highly
conditioned on the presence of specific cytogenetic and
molecular abnormalities. Among AMLs with abnormal cytogenet-
ics, the presence of t(8;21), t(15;17) or inv(16) is widely recognized
as conferring favorable prognosis, while a variety of other
chromosomal aberrations define a poor prognostic group.[1]
However, the majority of AMLs are cytogenetically normal
(CN) and collectively define an intermediate prognostic group.
Within the CN group, several molecular abnormalities have
been associated with prognosis. For example, FLT3-ITD carries
a unfavorable prognosis, while both NPM1 and CEBPA mutations
confer a favorable prognosis.[2]
Systematic application of gene expression profiling to
AML samples has revealed that major prognostic subgroups
based on cytogenetics and molecular markers are recapitu-
lated in large-scale gene expression patterns.[3] A large
body of AML gene expression profiling studies has emerged
together with reported correlations with pathogenesis,
diagnosis, risk classification, and outcome prediction.
[4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,
26,27,28,29,30,31,32,33] However, these studies have not
been systematically compared. Such a comparison has the
potential to test the extensibility of conclusions based on single
studies, and may provide further insights into AML pathogen-
esis while exposing potential diagnostic and prognostic markers
and therapeutic targets.
Ap r i o r i , there are two general approaches to comparing gene
expression profiling studies. The first and most rigorous
approach requires normalization and re-analysis of raw expres-
sion data. However, this approach is not practical in cases where
raw data are not available from a significant number of studies or
is in an unusable form. Indeed, a recent review revealed that only
one third of published papers have deposited raw data that are
considered robust enough to allow valid multi-study compari-
sons.[34] An alternative approach focuses on comparative
analysis of the published lists of significantly over-expressed or
under-expressed genes.[35] This type of analysis involves
discovery of gene intersections in published lists, and has been
effectively utilized in a variety of contexts such as identification of
biomarkers in thyroid and colorectal cancer.[36,37] Although
several tools and repositories have been developed to facilitate
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9466identification of significant gene intersections[38,39,40], the
heterogeneity of the published gene lists for AML require
development of a novel approach that will allow a fine-grained
comparison and analysis.
In this paper we describe a systematic, fine-grained multi-study
comparison of heterogeneous differentially expressed gene sets
emerging from 25 expression profiling studies of AML published
between 1999 and 2008. Our approach includes collection of the
published gene lists, standardized annotation of each listed gene
with identification tags, and a functional analysis of the gene lists
that are associated with each identification tag (Figure 1). We
identified high interest genes in AML along with genes and
functional gene ontology (GO) categories associated with
prognosis and common AML subtypes. We discovered many
robust novel prognostic molecular features that were undetected
in prior studies. Our results provide novel insights into AML
pathogenesis with potential diagnostic, prognostic, and thera-
peutic implications.
Results
Categorization of Differentially Expressed Genes
A total of 15,809 expression features were available from 25
studies, utilizing 10 different microarray platforms, and comprising
a total of 2,744 patient samples (Table 1). Of the 15,809
expression features, 7,416 were classified as up-regulated, 6,419
were classified as down-regulated, and 1,974 were not classified
with respect to an expression direction. A total of 14,385 (91%)
expression features could be mapped to a gene symbol in the
UCSC hg18 database, which comprised a total of 4,918 genes.
Standardized Annotation of Gene Expression Features
We annotated each expression feature with standardized identifica-
tion tags and comparison conditions. The identification tags are a set of
descriptors that describe the context of the expression feature, such as
the experiment type (RT-PCR or microarray) and the results including
prognostic category associations. The database contained 91 unique
identification tags (Table S1). The comparison conditions describe the
samples that are compared in each experiment and the database
contained 78 unique comparison conditions (Table S2).
Genes Associated with AML
We then identified genes that were reported in multiple studies. Of
the total 4,918 genes, 1,686 (34.3%) were reported in more than one
study. We ranked genes that were listed in at least 8 studies by number
of references, number of expression platforms, and number of
expression features (Table 2). Although most of these genes have
been associated with AML elsewhere in the literature, several genes
(VCAN and PGDS) were only described in AML cell lines and a
surprising number of the genes (HLA-DPA1, ITM2A, RBPMS, RGS10,
RNASE2 and TRH) were not specifically described in AML. VCAN is a
component of the extracellular matrix modulating cell adhesion, cell
proliferation, cell migration, and extracellular matrix assembly.[41]
High expression of VCAN has been found in many malignancies, such
as melanomas, ovarian, breast, and lung tumors,[41] and in the acute
monocytic leukemia cell line, THP-1.[42] PGDS is an enzyme that
catalyzes the conversion of PGH2 to PGD2, which is a prostaglandin
involved in vasodilation, bronchoconstriction, inhibition of platelet
aggregation, and recruitment of inflammatory cells.[43] PGDS
expression has been reported in two megakaryoblastic cell lines,
CMK and Dami.[43] TRH is a neurotransmitter/neuromodulator in
gene ontology analysis
Integrative Analysis
gene expression
 summaries
gene mapping
gene listings
Gene ID    Comparison Condition   Direction              Identification tags
…
207872_at     t(8;21) cluster       up-regulated        <microarray><t(8;21)>...
…
GNBH         inv(16) vs t(15;17)   up-regulated       <microarray><inv(16)>...
GNBH         inv(16) vs t(15;17)   down-regulated  <microarray><t(15;17)>...
... 
Published Gene Lists
...
...
...
Figure 1. Tag-based classification method flowchart.
doi:10.1371/journal.pone.0009466.g001
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hypothalamus to regulate the biosynthesis of TSH in the anterior
pituitary gland.[44] HLA-DPA1 is a HLA class II gene involved in
antigen presentation, and has been associated with esophageal
squamous dysplasia[45] and pilocytic astrocytomas[46]. RNASE2 is a
cationic ribonuclease toxin found in eosinophil granules[47] and
reported to have chemotactic[48] and antiviral[49] activities. RBPMS is
a RNA-binding protein withanunclearspecific function and at least 12
different splice variants.[50] ITM2A is a type II transmembrane
glycoprotein expressed in vesicles and on the cell surface and has been
noted to be up-regulated during T-cell activation.[51] ITM2A has been
associated with chrondrogenic[52] and myogenic differentiation[53].
RGS10 acts as a GTPase-activating protein via modulation of Gaia n d
Gaz signaling[54], and promotes chrondrogenic differentiation in
mice.[55] Expression of RGS10 has been noted in lymphocytes[56] and
rat platelets[57].
Concordant Gene Expression Identified in Multiple
Studies
We then identified prognostic categories that were reported in
greater than 3 independent studies and stratified these by number
of genes, differential expression direction, and number of
independent studies (Table 3). This analysis revealed the
existence of genes in categories of AML that were strictly up-
regulated or down-regulated across multiple studies.
Hierarchical Cluster Analyses of Differentially Expressed
Genes
We next performed hierarchical clustering of differentially
expressed genes associated with AML prognostic categories
(Figure 2A). We identified 5 major clusters. Cluster 1 includes
aneuploid, abnormal cytogenetics, CD34+CD38+ AML fraction,
high centrosome aberrations and poor prognosis. Cluster 2 includes
FAB-M4, FAB-M5, inv(16) and monocytic. Cluster 3 includes a
large group of heterogeneous identification tags. Cluster 4 identifies
FLT3-TKD, euploid, FAB-M7, CEBPA silenced, and NRAS-PM.
Cluster 5 includes FLT3 mutation, FLT3-ITD, normal cytogenetics
and NPM1 mutation. Cluster 1 corresponds to features noted in
poor prognosis AML, cluster 2 corresponds to features found in
monocytic differentiated AML, while cluster 5 includes AML
subtypes that are found in cytogenetically normal (CN) AML.
Hierarchical Cluster Analyses of Gene Functional
Categories
Next, we performed hierarchical cluster analyses of functional
categories associated with AML related identification tags
Table 1. Acute Myelogenous Leukemia expression profiling studies included in analysis.
Reference Platform Disease
No. of
samples
No. of differentially
expressed features
No. of differentially
expressed mapped
features
Golub et al, 1999
4 Affymetrix HU6000 AML/ALL 72 100 78
Okutsu et al, 2002
6 Custom cDNA 23,040 clones AML 76 491 355
Schoch et al, 2002
7 Affymetrix U95Av2 AML 37 150 140
Debernardi et al, 2003
8 Affymetrix U95Av2 AML 28 77 75
Kohlmann et al, 2003
9 Affymetrix U95Av2 Affymetrix U133A AML/ALL 90 156 147
Yagi et al, 2003
10 Affymetrix U95Av2 AML 54 1,910 1,753
Bullinger et al, 2004
11 Custom cDNA 39,711 clones AML 116 1,040 855
Lacayo et al, 2004
12 Custom cDNA 42,749 clones AML 100 436 329
Neben et al, 2004
13 Custom cDNA 4211 clones AML 29 170 162
Ross et al, 2004
14 Affymetrix U133A AML 150 713 682
Valk et al, 2004
*1 5 Affymetrix U133A AML 293 779 745
Vey et al, 2004
16 DiscoveryChip cDNA 9,039 clones AML 55 197 119
Alcalay et al, 2005
17 Affymetrix U133A AML 78 554 541
Gutierrez et al, 2005
18 Affymetrix U133A AML 43 181 167
Heuser et al, 2005
20 Custom cDNA 41,424 clones AML 137 178 146
Haferlach et al, 2005
19 Affymetrix U133A AML 35 20 19
Neben et al, 2005
21 Custom cDNA 4,211 clones AML 110 250 250
Verhaak et al, 2005
22 Affymetrix U133A AML 275 568 555
Radmacher et al, 2006
25 Affymetrix U133plus2.0 AML 64 314 304
Wilson et al, 2006
26 Affymetrix U95Av2 AML 170 705 674
Gal et al, 2006
23 Affymetrix U133A AML 5 822 724
Bullinger et al, 2007
27 Custom cDNA 39,711 clones AML 93 4,120 3,828
Eisele et al, 2007
28 Affymetrix U133A AML 11 82 82
Mullighan et al, 2007
33 Affymetrix U133A AML 93 1,188 1,095
Wouters et al, 2007
31 Affymetrix U133plus2.0 AML 530 608 560
Total 10 platforms 2,744 15,809 14,385
*Included further analysis of data by Verhaak 2005
22 and Wilson 2006
26.
doi:10.1371/journal.pone.0009466.t001
Gene Expression in AML
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9466(Figure 2B). We identified 6 clusters. Cluster 1 includes NPM1
mutation, good prognosis and normal cytogenetics. Cluster 2
includes NRAS-PM and MLL fusion gene. Cluster 3 includes
inv(16), high centrosome aberrations, abnormal cytogenetics,
11q23, aneuploid, CEBPA silenced, FAB-M7, and poor prognosis.
Cluster 4 includes FLT3 mutation, FLT3-ITD and t(11;19). Cluster
5 includes CD34+CD38+ AML fraction, CBF, FAB-M4, FAB-M5,
monocytic, and normal patient controls. Cluster 6 includes a large
group of heterogeneous identification tags. Cluster 1 corresponds to
features noted in good prognosis AML while cluster 3 corresponds
to several features noted in poor prognosis AML.
Analysis of HOX and TALE Gene Families
The HOX/TALE genes encode transcription factors regulating
pattern formation, differentiation, and proliferation, and there is
considerable evidence in the literature associating dysregulation of
HOX/TALE genes in AML. [58] We identified 24 homeodomain
(HOX/TALE) genes that were listed in at least one study (Table
S3). We observed an overall increase in HOX/TALE expression in
AML with normal cytogenetics, NPM1 mutations, FLT3 muta-
tions, and 11q23 abnormalities involving the MLL gene. Overall
decreases in HOX/TALE expression were observed in normal
CD34+ cells, AML with CEBPA mutations and AML with
abnormal cytogenetics, specifically t(15;17), t(8;21), and inv(16).
This pattern is consistent with previous RT-PCR studies screening
HOX/TALE genes expression levels[59,60,61,62,63,64], al-
though the association of CEBPA mutations with decreased
HOX/TALE expression has not been reported previously.
Analysis and Replication of Prognostic Categories
Next, we focused on genes associated with good and poor
prognosis. We defined ‘good prognosis’ as a relatively increased
overall survival or disease free survival or response to therapy. We
defined ‘poor prognosis’ as a relatively decreased overall survival
or disease free survival or response to therapy. The good prognosis
and poor prognosis gene sets are largely reciprocal. Surprisingly,
only 9.6% of these genes were replicated with concordant
expression directions in more than one study. The top ranked
up-regulated and down-regulated genes associated with poor
prognosis are shown in Table 4 and Table 5 respectively. The
top ranked up-regulated and down-regulated genes associated with
good prognosis are shown in Table S4.
Genes Associated with Prognosis
The majority of the top-ranked genes up-regulated in poor and
good prognosis, which are listed in Table 4, Table 5, and Table
Table 2. Genes most frequently published in AML expression studies.
Rank Gene symbol No. of references No. of platforms
No. of differentially
expressed features Gene name
1 HOXB2 12 6 32 homeobox B2
2 PBX3 12 5 31 pre-B-cell leukemia homeobox 3
3 HOXA9 11 4 35 homeobox A9
4 POU4F1 11 3 29 POU class 4 homeobox 1
5 TSPAN7 10 5 16 tetraspanin 7
6 MYH11 10 3 38 myosin, heavy chain 11, smooth muscle
7 RUNX1T1 10 3 34 runt-related transcription factor 1; translocated to, 1 (cyclin D-
related)
8 TRH 10 3 21 thyrotropin-releasing hormone
9 HLA-DPA1 10 3 20 major histocompatibility complex, class II, DP alpha 1
10 HOXB5 9 5 32 homeobox B5
11 SPARC 9 5 16 secreted protein, acidic, cysteine-rich (osteonectin)
12 HOXA10 9 4 34 homeobox A10
13 RNASE2 9 4 18 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin)
14 CD34 9 3 16 CD34 molecule
15 MEIS1 9 3 16 Meis homeobox 1
16 RUNX3 8 5 23 runt-related transcription factor 3
17 VCAN 8 5 22 versican proteoglycan
18 RBPMS 8 4 21 RNA binding protein with multiple splicing
19 HOXA4 8 4 18 homeobox A4
20 MN1 8 4 16 meningioma (disrupted in balanced translocation) 1
21 PRAME 8 4 11 preferentially expressed antigen in melanoma
22 JAG1 8 3 20 jagged 1 (Alagille syndrome)
23 ITM2A 8 3 18 integral membrane protein 2A
24 RGS10 8 3 17 regulator of G-protein signaling 10
25 PGDS
* 8 2 12 prostaglandin D2 synthase, hematopoietic
The genes reported in at least eight independent studies are presented here. In order of preference, the genes are ranked by the number of independent studies, the
number of unique platforms, and the total number of differentially expressed features.
*Gene symbol is not approved by HUGO Gene Nomenclature Committee.
doi:10.1371/journal.pone.0009466.t002
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Although not associated elsewhere with prognosis, HOXB5[65],
DAPK1[66], ANGPT1[67], TCF4[68], C3AR1[69], CAT[70],
IL6ST[71], JAG1[32], EZR[32], TP53BP2[72] and TNFAIP2[73]
have been described in AML. HOXA10, CD34, HOXA4, MN1,
NME1, FOXO1, NRP1, UGCG and FLT3 are the only genes listed
that have been associated with prognosis of AML in other studies.
These studies have described up-regulation of MN1[74],
NME1[75], HOXA10[59], and FLT3[76] in poor prognosis
AML which correlates with our comparison, while there are
conflicting reports of HOXA4[59,60] and CD34 gene expression in
poor prognosis AML. CD34 is notable and likely represents a false
positive result in our comparison. Although up-regulation of CD34
was initially described to correlate with a decreased response to
therapy,[77] it is has since been shown that up-regulation of this
gene actually correlates with abnormal cytogenetics, including
t(8;21), and is not associated with a decrease in overall survival or
disease-free survival.[78] Phosphorylation of FOXO1 has been
reported to correlate with decreased overall survival in AML,
although transcript expression levels have not been reported as
having any correlation with overall survival.[79] Up-regulation of
both NRP1[80] and UGCG[81] have been previously correlated
with decreased survival and chemoresistance in AML respectively,
which both contradict the results of our comparison.
Functional Categories and Prognosis
We then identified the functional categories associated with
poor prognosis and good prognosis. The specific over-represented
functional categories of the up-regulated genes and down-
regulated genes associated with poor prognosis and good prognosis
are summarized in Figure 3A. Detailed tables describing the
over-represented functional categories of up-regulated genes and
down-regulated genes associated with poor prognosis and good
prognosis are listed in Table S5, Table S6, Table S7 and
Table S8 respectively. Interestingly, many of the over-represented
functional categories of up-regulated genes associated with poor
prognosis were shared with up-regulated genes in aneuploidy, high
centrosome aberrations and CD34+CD38+ AML fraction, and
down-regulated genes in euploidy, low centrosome aberrations,
NPM1 mutations, good prognosis AML, CD34+CD38- AML
fraction, and FLT3-ITD. These results are consistent with
increased expression of genes involved in differentiation and
Table 3. Number of genes and independent publications with selected prognostic categories.
Tag (total genes)
(total references)
No. genes
in 1 study
No. genes
in 2 studies
No. genes
in 3 studies
No. genes
in 4 studies
No. genes
in 5 studies
No. genes
in 6 studies
No. genes
in 7 studies
No. genes
in 8 studies
poor prog (1727) (12) all genes 1559 138 27 3
up-regulated 586 28 2
down-regulated 943 55 10 1
good prog (1638) (11) all genes 1484 134 18 1 1
up-regulated 925 62 9 1
down-regulated 528 24 2
NPM1 mut (1169) (5) all genes 978 147 32 11 1
up-regulated 541 42 18 7 1
down-regulated 436 96 13 2
t(15;17) (230) (9) all genes 188 25 9 7 1
up-regulated 115 17 5 6
down-regulated 56 8 4 1 1
inv(16) (1322) (9) all genes 1197 88 23 7 6 1
up-regulated 533 44 12 7 2 1
down-regulated 285 15 4 1
t(8;21) (1195) (9) all genes 1057 92 23 15 4121
up-regulated 253 32 13 4 1 2 1
down-regulated 552 27 5 2
11q23 (482) (5) all genes 459 19 4
up-regulated 65 1
down-regulated 45 3
FLT3-ITD (235) (4) all genes 224 10 1
up-regulated 135 2
down-regulated 67
normal cyto (519) (6) all genes 480 36 3
up-regulated 173 1
down-regulated 206 6
The AML prognosis and subtype identification tags reported in greater than 3 independent studies are shown with the number of genes listed by number of
independent studies and differential expression direction. Identification tag descriptions can be found in Table S1. Note that the following tags are abbreviated: poor
prog is poor prognosis, good prog is good prognosis, NPM1 mut is NPM1 mutation, and normal cyto is normal cytogenetics.
doi:10.1371/journal.pone.0009466.t003
Gene Expression in AML
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9466Figure 2. Hierarchical cluster analyses. Strict up-regulation is green and strict down-regulation is red, while light blue represents no reported
specific direction. Identification tag descriptions can be found in Table S1. (A) Hierarchical cluster analysis of the 3998 differentially expressed genes
(x-axis) of AML prognostic categories (y-axis). For illustration purposes, we notated and manually separated 5 major clusters. Cluster 1 includes
aneuploid, abnormal cytogenetics, CD34+CD38+ AML fraction, high centrosome aberrations and poor prognosis. Cluster 2 includes FAB-M4, FAB-M5,
inv(16) and monocytic. Cluster 3 includes a large group of heterogenous identification tags. Cluster 4 identifies FLT3-TKD, euploid, FAB-M7, CEBPA
silenced, and NRAS-PM. Cluster 5 includes FLT3 mutation, FLT3-ITD, normal cytogenetics and NPM1 mutation. (B) Hierarchical cluster analysis of the
541 differential GO categories (x-axis) of AML prognostic categories (y-axis). For illustration purposes, we notated and manually separated 6 major
clusters. Cluster 1 includes NPM1 mutation, good prognosis and normal cytogenetics. Cluster 2 includes NRAS-PM and MLL fusion gene. Cluster 3
includes inv(16), high centrosome aberrations, abnormal cytogenetics, 11q23, aneuploid, CEBPA silenced, FAB-M7, and poor prognosis. Cluster 4
includes FLT3 mutation, FLT3-ITD and t(11;19). Cluster 5 includes CD34+CD38+ AML fraction, CBF, FAB-M4, FAB-M5, monocytic, and normal patient
controls. Cluster 6 includes a large group of heterogenous identification tags.
doi:10.1371/journal.pone.0009466.g002
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expression of genes involved in proliferation in poor prognosis
AML.
Analysis of Molecular and Cytogenetic Subtypes
We then surveyed specific molecular and cytogenetic subtypes
of AML that reported genes in greater than 3 independent studies.
This includes NPM1 mutations, t(15;17), inv(16), and t(8;21),
which are all known to portend a good prognosis. [1,82] The top-
ranked up-regulated and down-regulated genes associated with
NPM1 mutations, t(15;17), inv(16), and t(8;21) are shown in Table
S9, Table S10, Table S11 and Table S12 respectively. The
specific over-represented functional categories of the up-regulated
genes and down-regulated genes associated with NPM1 mutations,
t(15;17), inv(16), and t(8;21) are summarized in Figure 3B.
Notably, NPM1 mutation’s functional categories were concordant
with good prognosis AML. AML with t(15;17) illustrated down-
regulation of genes involved in the immune system. Interestingly,
t(8;21) and inv(16) mirrored each other in terms of direction of
their common functional categories because of the significant
proportion of studies that directly compared these two entities.
Detailed tables describing the over-represented functional catego-
ries of up-regulated genes and down-regulated genes associated
with NPM1 mutations, t(15;17), inv(16), and t(8;21) are listed in
Table S13, Table S14, Table S15, Table S16, Table S17,
Table S18, Table S19 and Table S20 respectively.
Discussion
We developed a methodology for the comparison of published
heterogeneous gene lists, and we developed a web application
(http://gat.stamlab.org) to facilitate access to the study data. This
approach permitted a granular multi-study comparison of gene
lists and functional gene ontology classifications. To our
knowledge, the body of published AML gene expression profiling
studies in the form of published gene lists has not been
systematically compared.
We extracted a list of 4918 genes that were reported in 25 gene
expression profiling studies of AML. We found that a considerable
amount of the genes (32.7%) were published in more than one
study, and we described a list of 25 genes that were reported in
greater than 8 studies. Although most of these genes have been
associated with AML elsewhere in the literature, several genes
(VCAN and PGDS) have only been described in AML cell lines and
a surprising number of the genes (HLA-DPA1, ITM2A, RBPMS,
Table 4. Top ranked up-regulated genes associated with poor prognosis.
Rank Gene symbol
No. of specific
references
Total no. of
references
Total no. of
platforms
Total no. of
differentially
expressed features Gene name
1 BCL11A 3 5 4 19 B-cell CLL/lymphoma 11A (zinc finger protein)
2 TBXAS1 3 5 4 11 thromboxane A synthase 1 (platelet,
cytochrome P450, family 5, subfamily A)
3 HOXB5 2 9 5 32 homeobox B5
4 HOXA10 2 9 4 34 homeobox A10
5 CD34 2 9 3 16 CD34 molecule
6 RBPMS 2 8 4 21 RNA binding protein with multiple splicing
7 HOXA4 2 8 4 18 homeobox A4
8 MN1 2 8 4 16 meningioma (disrupted in balanced
translocation) 1
9 GNAI1 2 6 3 12 guanine nucleotide binding protein (G
protein), alpha inhibiting, activity polypeptide
1
10 SKAP2 2 5 4 21 src kinase associated phosphoprotein 2
11 MCM3 2 5 4 9 minichromosome maintenance complex
component 3
12 CLIP2 2 5 3 8 CAP-GLY domain containing linker protein 2
13 DAPK1 2 5 3 8 death-associated protein kinase 1
14 GUCY1A3 2 4 4 8 guanylate cyclase 1, soluble, alpha 3
15 ANGPT1 2 4 3 11 angiopoietin 1
16 MTHFD1 2 4 3 6 methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 1,
methenyltetrahydrofolate cyclohydrolase,
formyltetrahydrofolate synthetase
17 MAP7 2 3 3 14 microtubule-associated protein 7
18 UGCGL2 2 3 3 11 UDP-glucose ceramide glucosyltransferase-like
2
19 SH2B3 2 3 3 6 SH2B adaptor protein 3
20 FLT3 2 3 3 5 fms-related tyrosine kinase 3
In order of preference, the genes are ranked by the number of poor prognosis related independent studies, the total number of independent studies, the total number
of unique platforms, and the total number of features. Genes that were also associated with good prognosis with the same expression direction are not shown.
doi:10.1371/journal.pone.0009466.t004
Gene Expression in AML
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9466RGS10, RNASE2 and TRH) have not been specifically described in
AML.
We identified gene sets that were associated with good prognosis
and poor prognosis (overall survival, disease free survival, or
response to therapy) in AML across multiple studies. Surprisingly,
only 9.6% of these genes were replicated with concordant
expression directions in more than one study. We surveyed the
higher ranked genes that were reported in multiple studies, and
noted the majority of these genes were not described elsewhere in
human AML.
We also identified functional gene ontology categories that are
associated with prognosis in AML, which are consistent with
increased expression of genes involved in differentiation and
apoptosis dysregulation in good prognosis AML and increased
expression of genes involved in proliferation in poor prognosis
AML. A study included in our comparison that examined survival
in CBF AML also associated up-regulation of proliferation GO
categories with decreased survival and associated up-regulation of
RNA metabolism and apoptosis dysregulation GO categories with
increased survival.[27]
We identified differentially expressed genes across multiple
studies that were associated with specific subtypes of AML
including t(15;17), inv(16), t(8;21), and NPM1 mutations. For
example, there were 5 papers in our comparison that reported
gene lists associated with NPM1 mutations, and all 5 of these
papers reported up-regulation of SMC4. Additionally, we also
identified functional gene ontology categories that were associated
with each of these AML subtypes. Interestingly, the functional
gene ontology sets of AML with the NPM1 mutation were similar
to good prognosis AML, which is expected considering NPM1
mutations impart a favorable prognosis.
Our comparison included 24 homeodomain (HOX/TALE)
genes with 7 listed in more than 7 papers. The HOX/TALE genes
encode transcription factors regulating pattern formation, differ-
entiation, and proliferation. Orderly HOX gene activation is
essential for normal hematopoiesis with HOX genes preferentially
expressed in the hematopoietic stem cell compartment and then
down-regulated following differentiation and maturation.[58]
There is considerable evidence in the literature associating
dysregulation of HOX/TALE genes in AML.[58] Constitutive
Table 5. Top ranked down-regulated genes associated with poor prognosis.
Rank Gene symbol
No. of specific
references
Total no. of
references
Total no. of
platforms
Total no. of
differentially
expressed features Gene name
1 EML4 4432 2 e c h i n oderm microtubule associated
protein like 4
2 C3AR1 3629 c omplement component 3a receptor 1
3S M G 1
* 3542 6 phosphatidylinositol 3-kinase-related
protein kinase
4 FOXO1 3541 5 f o r khead box O1
5 IL6ST 3431 8 i n terleukin 6 signal transducer (gp130,
oncostatin M receptor)
6 UGCG 3431 2 UDP-glucose ceramide
glucosyltransferase
7A D F P 3421 2 a d i p o s e d ifferentiation-related protein
8 AZU1 3428 a z u r o c i d i n 1 ( c a tionic antimicrobial
protein 37)
9 SNX9 3321 4 s o rting nexin 9
10 PIK3R4 3328 phosphoinositide-3-kinase, regulatory
subunit 4, p150
11 SEMA3F 3326 s e m a domain, immunoglobulin domain
(Ig), short basic domain, secreted,
(semaphorin) 3F
12 JAG1 2832 0 j a g g e d 1 ( A l a g ille syndrome)
13 CD3D 2742 1 CD3d molecule, delta (CD3-TCR
complex)
14 SLC7A7 2651 4 s o l u t e c a rrier family 7 (cationic amino
acid transporter, y+ system), member 7
15 ENDOD1 2641 3 e ndonuclease domain containing 1
16 GYPC 2641 1 g lycophorin C (Gerbich blood group)
17 ISG20 2631 7 i n terferon stimulated exonuclease gene
20 kDa
18 EZR 2541 3 Ezrin
19 AGRN 2541 2 A g r i n
20 NRP1 2539 n e u r o p ilin 1
In order of preference, the genes are ranked by the number of poor prognosis related independent studies, the total number of independent studies, the total number
of unique platforms, and the total number of features. Genes that were also associated with good prognosis with the same expression direction are not shown.
*Gene symbol is not approved by HUGO Gene Nomenclature Committee.
doi:10.1371/journal.pone.0009466.t005
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mice results in acute leukemia,[83,84,85,86] and recurrent
chromosomal translocations in humans involving HOXA9[87],
PBX1[88], and HOX11[89] results in leukemia. The MLL gene is a
known positive regulator of HOX/TALE expression and translo-
cations involving the MLL gene have been associated with
increased expression of HOXA4-11, MEIS1, and PBX1.[58]
Our comparison showed a general increase in HOX/TALE
expression in AML with normal cytogenetics, NPM1 mutations,
FLT3 mutations, and 11q23 abnormalities involving the MLL gene
while showing an overall decrease in HOX/TALE expression in
normal patient CD34+ cells, AML with CEBPA mutations and
AML with abnormal cytogenetics, specifically t(15;17), t(8;21), and
inv(16). All of the above trends, except for CEBPA mutations, have
been reported and confirmed in several RT-PCR stud-
ies.[59,60,61,62,63,64] To our knowledge, the association of
CEBPA mutations with decreased HOX/TALE expression has not
been reported previously. Several of the HOX/TALE genes,
specifically HOXB2, PBX3 and MEIS1, were also shown in our
comparison to have increased expression in inv(16) when
compared to t(8;21), which is supported by two recent RT-PCR
studies[59,60]. Exceptions to the above trends in our comparison
include decreased expression of HOXB2 with MLL translocations,
decreased expression of PBX2 with MLL translocations and NPM1
mutations, and decreased expression of HOXC4 with NPM1
mutations.
Several RT-PCR studies have associated increased expression
of HOXA1-10 and MEIS1 with decreased overall survival in
AML,[59,61] although recently a RT-PCR study did associate
decreased expression of HOXA4 with decreased overall survival in
CN AML[60]. Several RT-PCR studies have also associated high
risk cytogenetics with increased expression of HOX/TALE
genes[58,61] and an RT-PCR study has associated increased
expression of FLT3 or FLT3 mutations in CN AML with increased
expression of HOX/TALE genes[63]. In poor prognosis (includes
decreased overall survival, disease free survival, or response to
therapy) AML, our comparison showed increased expression of
several HOX/TALE genes, specifically HOXA4, HOXA10, HOXB5
and PBX1, while showing decreased expression of MEIS1 and
contradictory expression directions of HOXB2 and PBX3.
Although an overall increase of HOX/TALE expression in poor
prognosis AML has been reported, there are several contradictions
to this including MEIS1, HOXB2 and PBX3 in our comparison and
HOXA4 in an outside RT-PCR study[60]. Additionally, the overall
trend of increased HOX/TALE expression in poor prognosis AML
does not appear specific because our comparison and the literature
also report increased expression of HOX/TALE genes in CN AML
and AML with NPM1 mutations. This point is well illustrated by
an RT-PCR study using a classifier with 17 homeodomain genes
that was able to differentiate favorable cytogenetics from
intermediate/unfavorable cytogenetics, however unable to differ-
entiate intermediate from unfavorable cytogenetics.[59]
There were several intriguing potential targets of therapy
uncovered during our analysis. TBXAS1 is an enzyme that
converts prostaglandin H2 into thromboxane A2.[90] Thrombox-
ane A2 induces platelet aggregation, smooth muscle contraction,
and possibly modulates mitogenesis and apoptosis.[91] Although
there have been no previous reports describing TBXAS1
expression in AML, our comparison included three papers that
associated increased expression of TBXAS1 with a poor prognosis.
In bladder cancer cells, pharmacologic inhibition of TBXAS1 with
furegrelate or ozagrel induced apoptosis and enhanced sensitivity
to chemotherapy,[92] which does suggest that pharmacologic
inhibition of this enzyme has potential for treatment in AML.
Figure 3. Functional category comparisons. (A) Significantly over-
represented functional gene ontology (GO) categories of interest in up-
regulated and down-regulated genes found in poor prognosis and
good prognosis are compared; the comprehensive functional gene
ontology listings can be found in Table S5, Table S6, Table S7, and Table
S8. (B) Significantly over-represented functional gene ontology (GO)
categories of interest in up-regulated and down-regulated genes found
in AML with NPM1 mutation, t(15;17), t(8;21) and inv(16) are compared;
the comprehensive functional gene ontology listings can be found in
Table S13, Table S14, Table S15, Table S16, Table S17, Table S18, Table
S19, Table S20. Corrected p-value is the Bonferroni multiple hypothesis.
doi:10.1371/journal.pone.0009466.g003
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a axon guidance factor, a tumor suppressor gene in small cell lung
cancer, a inhibitor of angiogenesis, and a possible direct inhibitor
of tumor cell migration and attachment.[93] Although there have
been no previous reports describing SEMA3F expression in AML,
our comparison included three papers that associated increased
expression of SEMA3F with a good prognosis, which suggest that a
SEMA3F analog could have potential for treatment in AML.
Our methodology was shown to be especially useful in
systematically identifying commonly reported genes and pathways
in the heterogeneous disease of AML. Our method is flexible and
ensures the inclusion of all pertinent studies into the analysis and is
accompanied by an online analysis and database querying tool for
other investigators. To ensure the inclusion of all possible pertinent
studies, our methodology does not require raw data and can
incorporate both published differential gene lists that are not
quantified and published gene lists with no reported direction of
expression (12% of the published expression features were not
associated with a direction). Another strategy that utilizes gene list
comparisons across studies has been published by Griffith et al.
and Chan et al.[36,37] Their method successfully identified
biomarkers in thyroid and colorectal cancer, however, we chose
not to employ their method because each feature requires an
explicit expression direction and a quantified expression value.
A potential disadvantage of our methodology is the wide variety
of methods employed by the individual studies, which include
sample populations, sample sizes, microarray platform types,
statistical analysis methods, and the ultimate decisions of which
gene lists the authors decide to publish. This heterogeneity in
methods can also be viewed as an advantage. For example, a gene
that is listed in two studies that employ different microarray
platforms and statistical methods could be considered more
meaningful than a gene that is listed in two studies that employ
the same microarray platform and statistical methodology.
Another potential disadvantage with our methodology is publica-
tion bias, because our results are dependent on gene lists the
authors have decided to publish within their respective studies. To
avoid the introduction of any further bias into our results, we do
not attempt to weigh the importance of each study by quality
metrics, such as sample size or data quality, thus the resulting gene
rankings are simply primarily based on the number of applicable
studies the gene was reported in.
In the future, our methodology could be applied to perform
comparisons of other malignancies and disease states. The main
limitations include the tedious process required to collect the gene
lists and the potential for publication bias. However, despite these
limitations, our methodology is especially powerful in systemati-
cally identifying commonly reported genes and pathways in
heterogeneous diseases, such as AML, and is especially useful in
cases where the raw gene expression datasets are not available.
Materials and Methods
Data Collection and Curation
We queried Pubmed for acute myeloid leukemia expression
profiling studies published between 1999 and early 2008. We
excluded studies that predominantly examined non-leukemia cells
and studies that contained less than 5 patient samples. In total,
published gene lists were collected from 25 independent studies
(Table 1). The published gene lists were processed to obtain the
following information: gene symbol; unique identifiers (Accession
ID, Affymetrix probe ID, LocusLink ID, UniGene ID); compar-
ison conditions; differential expression; microarray platform;
number of samples; PubMed ID; and identification tags. The
identification tags are a set of descriptors that describe each
expression feature. If two conditions were being compared, then
two separate expression features were created with opposite
differential expression and opposing identification tags. The
notation of the comparison conditions and the identification tags
in the database were standardized to allow the gene expression
summary analysis and gene ontology analysis, which are both
described below. The above processing was accomplished with a
combination of parsing with custom Perl scripts, manual
transcription, and copying/pasting. This information was then
enumerated and formatted with custom Perl scripts to create a flat
file database.
Gene Mapping
The expression features in the collected published lists were
referenced by one or more of the following: gene symbol, accession
ID, Affymetrix probe ID, LocusLink ID, and/or UniGene ID.
These references were mapped to the Gene Symbol in the UCSC
human genome hg18 database [94] with custom Perl scripts. If we
were unable to map the reference to a Gene Symbol in the UCSC
database, then the expression feature was not included in further
analysis.
Tag-Based Classification of Expression with Prognostic
Features
We used an integrative approach to assign identification ‘‘tags’’
to gene expression and prognostic categories. A flow chart of the
approach is illustrated in Figure 1. We assigned identification tags
to each datapoint and used a strict nomenclature for comparison
conditions.
Gene Expression Summary
We developed a customized Perl script that incorporates the
comparison conditions and identification tags in an algorithm to
summarize the expression directions of each mapped gene. These
expression summaries can be viewed in an online Browser (http://
gat.stamlab.org).(B.G.M and J.A.S., manuscript in preparation)
Functional Classification of Gene Lists
For functional classification of the gene lists, we used
GO::TermFinder[95] for gene ontology (GO)[96]analysis. We
downloaded the GO v1.0 OBO database 2/22/2008 release from
http://www.geneontology.org. We downloaded the human anno-
tation file version 60.0 and human cross-reference file version 3.39
from the GOA website http://www.ebi.ac.uk/GOA/. We devel-
oped custom Perl scripts to create a list of genes that was associated
with each identification tag and differential expression direction.
These lists of genes were then mapped to the appropriate Swiss-
Prot ID with the above mentioned GOA human cross-reference
file. To avoid an over-representation bias, we only allowed one
Swiss-Prot ID per gene. Statistically significant over-represented
GO categories of the Swiss-Prot ID lists were identified with
GO:TermFinder; we used the entire GO annotation as the
background, and statistical significance was calculating by the
Bonferroni multiple hypothesis with a p-value cutoff of 0.01.
Clustering Analysis
Hierarchical clustering was used to compare the differential
expression of elements (genes or gene ontology categories)
associated with each identification tag. For each identification
tag, strictly up-regulated elements were assigned the value 1, while
strictly down-regulated elements were assigned the value 0.
Hierarchical clustering was then calculated in the R software
Gene Expression in AML
PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9466package, which employed the method of complete linkage and
Canberra distance.
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